[1]
|
Arnett, D.K., Blumenthal, R.S., Albert, M.A., et al. (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Associa-tion Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 74, 1376-1414.
https://doi.org/10.1016/j.jacc.2019.03.009
|
[2]
|
Jacobson, T.A., Ito, M.K., Maki, K.C., et al. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clin-ical Lipidology, 9, 129-169.
https://doi.org/10.1016/j.jacl.2015.02.003
|
[3]
|
Khetarpal, S.A. and Rader, D.J. (2015) Triglyceride-Rich Lipopro-teins and Coronary Artery Disease Risk: New Insights from Human Genetics. Arteriosclerosis, Thrombosis, and Vas-cular Biology, 35, e3-e9.
https://doi.org/10.1161/ATVBAHA.114.305172
|
[4]
|
Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., et al. (2019) 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cho-lesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73, e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003
|
[5]
|
Mach, F., Baigent, C., et al. (2019) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: The Task Force for the Man-agement of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal, 41, 111-188.
|
[6]
|
Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., et al. (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. Lancet, 376, 1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
|
[7]
|
Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine, 372, 2387-2397.
https://doi.org/10.1056/NEJMoa1410489
|
[8]
|
Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiv-iott, S.D., Murphy, S.A., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722.
https://doi.org/10.1056/NEJMoa1615664
|
[9]
|
Maki, K.C. (2018) The ODYSSEY Outcomes Trial: Clinical Impli-cations and Exploration of the Limits of What Can Be Achieved through Lipid Lowering. Journal of Clinical Lipidology, 12, 1102-1105.
https://doi.org/10.1016/j.jacl.2018.05.016
|
[10]
|
Abifadel, M., Varret, M., Rabès, J.P., Allard, D., Ouguerram, K., Devillers, M., et al. (2003) Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia. Nature Genetics, 34, 154-156. https://doi.org/10.1038/ng1161
|
[11]
|
Cohen, J.C., Boerwinkle, E., Mosley, T.H. and Hobbs, H.H. (2006) Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. The New England Journal of Medicine, 354, 1264-1272.
https://doi.org/10.1056/NEJMoa054013
|
[12]
|
Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al. (2015) Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. The New England Journal of Medicine, 372, 1500-1509.
https://doi.org/10.1056/NEJMoa1500858
|
[13]
|
Toth, P.P., Barter, P.J., Rosenson, R.S., Boden, W.E., Chapman, M.J., Cuchel, M., et al. (2013) High-Density Lipoproteins: A Consensus Statement from the National Lipid Association. Journal of Clinical Lipidology, 7, 484-525.
https://doi.org/10.1016/j.jacl.2013.08.001
|
[14]
|
Di Angelantonio, E., Sarwar, N., Perry, P., et al. (2009) Major Li-pids, Apolipoproteins, and Risk of Vascular Disease. JAMA, 302, 1993-2000. https://doi.org/10.1001/jama.2009.1619
|
[15]
|
Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. (2012) Plasma HDL Cholesterol and Risk of Myocardial Infarction: A Mendelian Randomisation Study. Lancet, 380, 572-580. https://doi.org/10.1016/S0140-6736(12)60312-2
|
[16]
|
Boden, W.E., Probstfield, J.L., Anderson, T., et al. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267.
https://doi.org/10.1056/NEJMoa1107579
|
[17]
|
Schwartz, G.G., Olsson, A.G., Abt, M., et al. (2012) Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. The New England Journal of Medicine, 367, 2089-2099. https://doi.org/10.1056/NEJMoa1206797
|
[18]
|
Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2017) Extreme High High-Density Lipoprotein Cholesterol Is Paradoxically Associated with High Mortality in Men and Women: Two Prospective Cohort Studies. European Heart Journal, 38, 2478-2486. https://doi.org/10.1093/eurheartj/ehx163
|
[19]
|
Rohatgi, A., Westerterp, M., von Eckardstein, A., et al. (2021) HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. Circulation, 143, 2293-2309. https://doi.org/10.1161/CIRCULATIONAHA.120.044221
|
[20]
|
Yu, K.C. and Cooper, A.D. (2001) Postprandial Lipoproteins and Atherosclerosis. Frontiers in Bioscience, 6, 332-354.
https://doi.org/10.2741/Yu
|
[21]
|
Balling, M., Afzal, S., Varbo, A., Langsted, A., Smith, G.D. and Nordestgaard, B.G. (2020) VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated with apoB-Containing Lipoproteins. Journal of the American College of Cardiology, 76, 2725-2735. https://doi.org/10.1016/j.jacc.2020.09.610
|
[22]
|
Joshi, P.H., Khokhar, A.A., Massaro, J.M., Lirette, S.T., Griswold, M.E., Martin, S.S., et al. (2016) Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 5, e002765. https://doi.org/10.1161/JAHA.115.002765
|
[23]
|
Elshazly, M.B., Mani, P., Nissen, S., et al. (2020) Remnant Cho-lesterol, Coronary Atheroma Progression and Clinical Events in Statintreated Patients with Coronary Artery Disease. European Journal of Preventive Cardiology, 27, 1091-1100. https://doi.org/10.1177/2047487319887578
|
[24]
|
Lin, A., Nerlekar, N., Rajagopalan, A., et al. (2019) Remnant Cholesterol and Coronary Atherosclerotic Plaque Burden As-sessed by Computed Tomography Coronary Angiography. Atherosclerosis, 284, 24-30.
https://doi.org/10.1016/j.atherosclerosis.2019.02.019
|
[25]
|
Schwartz, G.G., Abt, M., Bao, W., et al. (2015) Fasting Triglycerides Predict Recurrent Ischemic Events in Patients with Acute Coronary Syndrome Treated with Statins. Journal of the American College of Cardiology, 65, 2267-2275.
https://doi.org/10.1016/j.jacc.2015.03.544
|
[26]
|
Faergeman, O., Holme, I., Fayyad, R., et al. (2009) Plasma Tri-glycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering Trials of Statins in Patients with Coronary Artery Disease. The American Journal of Cardi-ology, 104, 459-463.
https://doi.org/10.1016/j.amjcard.2009.04.008
|
[27]
|
Vallejo-Vaz, A.J., Fayyad, R., Boekholdt, S.M., et al. (2018) Triglyceride Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 138, 770-781.
https://doi.org/10.1161/CIRCULATIONAHA.117.032318
|
[28]
|
Khera, A.V., Won, H.H., Peloso, G.M., et al. (2017) Association of Rare and Common Variation in the Lipoprotein Lipase Gene with Coronary Artery Disease. JAMA, 317, 937-946. https://doi.org/10.1001/jama.2017.0972
|
[29]
|
Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar, N., Sandhu, M.S., Ricketts, S.L., et al. (2010) Triglyceride-Mediated Pathways and Coronary Disease: Collaborative Analysis of 101 Studies. Lancet, 375, 1634-1639. https://doi.org/10.1016/S0140-6736(10)60545-4
|
[30]
|
Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., As-simes, T.L., Thompson, J.R., et al. (2013) Large-Scale Association Analysis Identifies New Risk Loci for Coronary Ar-tery Disease. Nature Genetics, 45, 25-33.
https://doi.org/10.1038/ng.2480
|
[31]
|
Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., White, I.R., et al. (2009) Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA, 302, 412-423.
https://doi.org/10.1001/jama.2009.1063
|
[32]
|
Khera, A.V., Everett, B.M., Caulfield, M.P., et al. (2014) Lipoprotein (a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial (Justifica-tion for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 129, 635-642.
https://doi.org/10.1161/CIRCULATIONAHA.113.004406
|
[33]
|
Albers, J.J., Slee, A., O’Brien, K.D., et al. (2013) Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology, 62, 1575-1579. https://doi.org/10.1016/j.jacc.2013.06.051
|